Entering an era of radiogenomics in prostate cancer risk stratification

Nachiketh Soodana-Prakash, Radka Stoyanova, Abhishek Bhat, Maria C. Velasquez, Omer E. Kineish, Alan Pollack, Dipen J Parekh, Sanoj Punnen

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer.

Original languageEnglish (US)
Pages (from-to)S443-S452
JournalTranslational Andrology and Urology
Volume7
DOIs
StatePublished - Sep 1 2018

Fingerprint

Prostatic Neoplasms
Magnetic Resonance Imaging
Genomics
Clinical Decision-Making

Keywords

  • Genomics assays
  • Personalized information
  • Prostate cancer
  • Radiogenomics
  • Risk stratification

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology

Cite this

Entering an era of radiogenomics in prostate cancer risk stratification. / Soodana-Prakash, Nachiketh; Stoyanova, Radka; Bhat, Abhishek; Velasquez, Maria C.; Kineish, Omer E.; Pollack, Alan; Parekh, Dipen J; Punnen, Sanoj.

In: Translational Andrology and Urology, Vol. 7, 01.09.2018, p. S443-S452.

Research output: Contribution to journalReview article

Soodana-Prakash, Nachiketh ; Stoyanova, Radka ; Bhat, Abhishek ; Velasquez, Maria C. ; Kineish, Omer E. ; Pollack, Alan ; Parekh, Dipen J ; Punnen, Sanoj. / Entering an era of radiogenomics in prostate cancer risk stratification. In: Translational Andrology and Urology. 2018 ; Vol. 7. pp. S443-S452.
@article{fccb9f13e16b440cb09ef8d1c9403012,
title = "Entering an era of radiogenomics in prostate cancer risk stratification",
abstract = "Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer.",
keywords = "Genomics assays, Personalized information, Prostate cancer, Radiogenomics, Risk stratification",
author = "Nachiketh Soodana-Prakash and Radka Stoyanova and Abhishek Bhat and Velasquez, {Maria C.} and Kineish, {Omer E.} and Alan Pollack and Parekh, {Dipen J} and Sanoj Punnen",
year = "2018",
month = "9",
day = "1",
doi = "10.21037/tau.2018.07.04",
language = "English (US)",
volume = "7",
pages = "S443--S452",
journal = "Translational Andrology and Urology",
issn = "2223-4683",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Entering an era of radiogenomics in prostate cancer risk stratification

AU - Soodana-Prakash, Nachiketh

AU - Stoyanova, Radka

AU - Bhat, Abhishek

AU - Velasquez, Maria C.

AU - Kineish, Omer E.

AU - Pollack, Alan

AU - Parekh, Dipen J

AU - Punnen, Sanoj

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer.

AB - Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer.

KW - Genomics assays

KW - Personalized information

KW - Prostate cancer

KW - Radiogenomics

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=85053434513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053434513&partnerID=8YFLogxK

U2 - 10.21037/tau.2018.07.04

DO - 10.21037/tau.2018.07.04

M3 - Review article

AN - SCOPUS:85053434513

VL - 7

SP - S443-S452

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

SN - 2223-4683

ER -